Enlivex Therapeutics (ENLV) Institutional Ownership $1.05 +0.01 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.06 +0.01 (+0.95%) As of 08/29/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Enlivex Therapeutics (NASDAQ:ENLV)CurrentInstitutional OwnershipPercentage1.02%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$982.55KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$848.30K Get ENLV Insider Trade Alerts Want to know when executives and insiders are buying or selling Enlivex Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data ENLV Institutional Buying and Selling by Quarter Enlivex Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/14/2025 Jane Street Group LLC61,052$68K0.0%-24.4%0.258% 8/14/2025 Armistice Capital LLC1,413,306$1.58M0.0%-20.7%5.976% 5/19/2025 Jane Street Group LLC80,759$78K0.0%+527.4%0.341% 5/15/2025 Armistice Capital LLC1,781,931$1.73M0.0%-19.3%7.534% 2/17/2025 Millennium Management LLC633,847$742K0.0%N/A2.961% 2/14/2025 Two Sigma Securities LLC22,362$26K0.0%N/A0.104% 2/13/2025 Renaissance Technologies LLC158,992$186K0.0%+112.6%0.743% 10/23/2024 Sigma Investment Counselors Inc.30,000$50K0.0%N/A0.140% 8/15/2024 Armistice Capital LLC1,700,571$2.42M0.0%N/A8.148% 8/12/2024 XTX Topco Ltd24,820$35K0.0%N/A0.119% Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/1/2023 Compagnie Lombard Odier SCmA65,000$225K0.0%+30.0%0.350% 2/9/2023 Group One Trading L.P.13,499$53K0.0%+2,689.0%0.073% 7/11/2022 ARK Investment Management LLC331,001$1.66M0.0%-23.8%1.802% 4/27/2022 Compagnie Lombard Odier SCmA50,000$279K0.0%+16.3%0.273% 4/20/2022 Belvedere Trading LLC14,473$101K0.0%-13.9%0.079% 4/19/2022 ARK Investment Management LLC434,343$2.43M0.0%+24.3%2.372% 2/9/2022 Compagnie Lombard Odier SCmA43,000$247K0.0%+22.9%0.235% 2/3/2022ACT Capital Management LLC25,000$156K0.1%-69.7%0.137% 1/28/2022 ARK Investment Management LLC349,308$2.18M0.0%-23.7%1.908% 1/21/2022Golden Green Inc.19,967$125K0.1%-54.7%0.109% 11/12/2021 Renaissance Technologies LLC87,989$869K0.0%-55.0%0.481% 10/28/2021 Compagnie Lombard Odier SCmA35,000$353K0.0%+40.0%0.191% 10/8/2021Golden Green Inc.44,085$436K0.3%-4.2%0.241% 8/13/2021 Renaissance Technologies LLC195,706$1.74M0.0%-32.6%1.242% 8/11/2021 Banque Cantonale Vaudoise10,000$89K0.0%N/A0.063% (Data available from 1/1/2016 forward) ENLV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENLV shares? During the previous two years, the following institutional investors and hedge funds held shares of Enlivex Therapeutics shares: Armistice Capital LLC ($1.58M), Millennium Management LLC ($742K), Renaissance Technologies LLC ($186K), Jane Street Group LLC ($68K), Sigma Investment Counselors Inc. ($50K), and XTX Topco Ltd ($35K), and Two Sigma Securities LLC ($26K).Learn more on Enlivex Therapeutics' institutional investors. What percentage of Enlivex Therapeutics' stock is owned by institutional investors? 1.02% of Enlivex Therapeutics' stock is owned by institutional investors. Learn more on ENLV's institutional investor holdings. Which institutional investors have been buying Enlivex Therapeutics' stock? The following institutional investors have purchased Enlivex Therapeutics' stock in the last 24 months: Armistice Capital LLC ($1.70M), Millennium Management LLC ($633.85K), Renaissance Technologies LLC ($84.20K), Jane Street Group LLC ($67.89K), Sigma Investment Counselors Inc. ($30K), XTX Topco Ltd ($24.82K), and Two Sigma Securities LLC ($22.36K). How much institutional buying is happening at Enlivex Therapeutics? Institutional investors have bought a total of 838,298 shares in the last 24 months. This purchase volume represents approximately $982.55K in transactions. Which of Enlivex Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Enlivex Therapeutics stock in the last 24 months: Armistice Capital LLC ($794.69K), and Jane Street Group LLC ($19.71K). How much institutional selling is happening at Enlivex Therapeutics? Institutional investors have sold a total of 814,401 shares in the last 24 months. This volume of shares sold represents approximately $848.30K in transactions. Related Companies ANIX Institutional Ownership SRZN Institutional Ownership CRDL Institutional Ownership XBIT Institutional Ownership VTGN Institutional Ownership IMUX Institutional Ownership ABOS Institutional Ownership EPIX Institutional Ownership CELU Institutional Ownership OKYO Institutional Ownership This page (NASDAQ:ENLV) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
